• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session

    1/9/23 1:42:49 PM ET
    $ALBO
    $AMYT
    $APGN
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALBO alert in real time by email

    Gainers

    • CinCor Pharma, Inc. (NASDAQ:CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.
    • Apexigen, Inc. (NASDAQ:APGN) jumped 111% to $1.99 after climbing more than 10% on Friday.
    • Amryt Pharma plc (NASDAQ:AMYT) gained 106.7% to $14.49 after Chiesi Farmaceutici announced it will acquire the company for $14.50 per ADS plus contingent value rights of up to an additional $2.50 per ADS.
    • Albireo Pharma, Inc. (NASDAQ:ALBO) shares climbed 92.9% to $44.03 after Ipsen announced it will acquire the company for $42 per share plus a contingent value right of $10 per share.
    • Duck Creek Technologies, Inc. (NASDAQ:DCT) gained 47% to $19.10 after the company agreed to be acquired by Vista Equity Partners for $2.6 billion.
    • Revance Therapeutics, Inc. (NASDAQ:RVNC) surged 43% to $28.25 as the company reported the FDA acceptance Of supplemental Biologics License Application for DAXXIFY for injection for the treatment of cervical dystonia.
    • Novo Integrated Sciences, Inc. (NASDAQ:NVOS) rose 35.9% to $0.2052. Novo Integrated Sciences recently reported it entered an agreement to purchase 100% of shares of SWAG in exchange for $1.00.
    • Sema4 Holdings Corp. (NASDAQ:SMFR) gained 34% to $0.3299. Sema4 sees preliminary 2022 pro-forma revenues of $170 million to $173 million.
    • Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) gained 32% to $2.02. Comera Life Sciences 10% owner Charles Cherington bought a total of 743,243 shares at an average price of $1.23.
    • Party City Holdco Inc. (NYSE:PRTY) climbed 31.9% to $0.2363. Party City shares dropped 50% on Friday following a report suggesting the company has hired a restructuring advisor and plans a bankruptcy filing within weeks.
    • Bed Bath & Beyond Inc. (NASDAQ:BBBY) rose 30.9% to $1.7150. Bed Bath & Beyond shares dropped over 22% on Friday following a report indicating the company could file for bankruptcy in the coming weeks.
    • CureVac N.V. (NASDAQ:CVAC) shares rose 30.4% to $10.77. CureVac shares jumped over 29% on Friday after the company announced data on joint COVID-19 and flu mRNA vaccine development programs.
    • ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) jumped 28% to $2.06.
    • Better Choice Company Inc. (NYSE:BTTR) gained 28% to $0.7293.
    • Hempacco Co., Inc. (NASDAQ:HPCO) rose 28% to $1.19.
    • Bit Digital, Inc. (NASDAQ:BTBT) gained 28% to $0.9498. Bit Brother regained compliance with Nasdaq minimum bid price requirements for continued listing.
    • Celyad Oncology SA (NASDAQ:CYAD) jumped 25.1% to $0.7482. Celyad Oncology recently reported it has decided to discontinue the development of its remaining clinical program CYAD-211.
    • Paya Holdings Inc. (NASDAQ:PAYA) gained 24.5% to $9.70 after Nuvei entered into a definitive agreement to acquire the company for $9.75 per share in cash.
    • LexinFintech Holdings Ltd. (NASDAQ:LX) jumped 24.5% to $2.9892.
    • Xos, Inc. (NASDAQ:XOS) jumped 23.3% to $1.00.
    • NanoString Technologies, Inc. (NASDAQ:NSTG) surged 23.1% to $9.77. NanoString issued preliminary financial and operational highlights for Q4 and FY 2022.
    • Greenidge Generation Holdings Inc. (NASDAQ:GREE) gained 22.1% to $0.4780.
    • Barfresh Food Group, Inc. (NASDAQ:BRFH) gained 21.1% to $1.49.
    • Grove Collaborative Holdings, Inc. (NYSE:GROV) jumped 20.6% to $0.5790.
    • Exact Sciences Corporation (NASDAQ:EXAS) gained 20.5% to $56.85 after the company announced preliminary Q4 results.
    • Tempo Automation Holdings, Inc. (NASDAQ:TMPO) jumped 20% to $1.26.
    • Kronos Bio, Inc. (NASDAQ:KRON) jumped 19.7% to $2.06. Kronos Bio announced discovery collaboration with Genentech to advance novel therapies against transcriptional targets in oncology.
    • Bitfarms Ltd. (NASDAQ:BITF) gained 19.4% to $0.65.
    • Guardion Health Sciences, Inc. (NASDAQ:GHSI) jumped 19.4% to $7.10.
    • Lufax Holding Ltd (NYSE:LU) jumped 17.5% to $2.5400.
    • Marathon Digital Holdings, Inc. (NASDAQ:MARA) gained 15.5% to $4.7250. Jefferies downgraded Marathon Digital from Buy to Hold and announced a $4 price target.
    • Coinbase Global, Inc. (NASDAQ:COIN) rose 12.5% to $37.42. Jefferies initiated coverage on Coinbase Global with a Hold rating and announced a price target of $35.
    • Riot Blockchain, Inc. (NASDAQ:RIOT) gained 12% to $4.78. Wells Fargo maintained Riot Platforms with an Equal-Weight and lowered the price target from $6 to $5.
    • Viracta Therapeutics, Inc. (NASDAQ:VIRX) rose 10.3% to $1.81 after the company announced first clinical response in epstein-barr virus-positive (EBV+) solid tumor setting.
    • Zillow Group, Inc. (NASDAQ:Z) gained 8.7% to $39.01 after B of A Securities upgraded the stock from Underperform to Buy and raised its price target from $22 to $42.
    • Tesla, Inc. (NASDAQ:TSLA) jumped 8.3% to $122.44 amid vehicle price cuts in China and indications that wait times for some Chinese Model Y vehicles have increased.
    • Snowflake Inc. (NYSE:SNOW) rose 8% to $133.93. Piper Sandler maintained Snowflake with an Overweight and lowered the price target from $200 to $194.


    Losers

    • Calithera Biosciences, Inc. (NASDAQ:CALA) shares dipped 80.1% to $0.72. Calithera Biosciences announced board approval of complete liquidation and dissolution.
    • MultiMetaVerse Holdings Limited (NASDAQ:MMV) fell 58.4% to $4.81 after jumping 82% on Friday.
    • Moolec Science SA (NASDAQ:MLEC) fell 41.3% to $11.30 after jumping 258% on Friday.
    • Peak Bio, Inc. (NASDAQ:PKBO) dropped 28.8% to $2.5910.
    • Cutera, Inc. (NASDAQ:CUTR) fell 23.4% to $30.97 after the company reported preliminary unaudited financial results for FY22. The company expects to report revenue in the range of $252 million to $253 million for FY22.
    • AMTD Digital Inc. (NYSE:HKD) dropped 20.6% to $18.20.
    • Cerus Corporation (NASDAQ:CERS) fell 20.5% to $3.0060. Cerus sees preliminary Q4 product revenues of $44 million, up 10% year over year.
    • Golden Sun Education Group Limited (NASDAQ:GSUN) declined 19.5% to $1.8060.
    • Magic Empire Global Limited (NASDAQ:MEGL) dropped 19.5% to $2.23.
    • Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) fell 18.6% to $30.41. Takeda Pharmaceutical Co and Arrowhead Pharmaceuticals announced topline results from the Phase 2 SEQUOIA study of fazirsiran (TAK-999/ARO-AAT) for liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD).
    • First Wave BioPharma, Inc. (NASDAQ:FWBI) dropped 17% to $0.8720.
    • Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) declined 17% to $6.57. Monte Rosa Therapeutics outlined progress across portfolio of molecular glue degraders and key anticipated milestones for 2023.
    • Arvinas, Inc. (NASDAQ:ARVN) dropped 15.8% to $28.68. Arvinas said the company and Pfizer have proposed a modification to planned Veritac-3 Phase 3 study.
    • Infobird Co., Ltd (NASDAQ:IFBD) fell 14.8% to $0.7999.
    • Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) dropped 14.4% to $45.92. Harmony Biosciences named Jeffrey M. Dayno, MD as interim CEO and expands role of Jeff Aronin to executive chairman.
    • BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) fell 11.2% to $10.50 after the company reported preliminary FY22 ORLADEYO net revenue results and issued FY23 ORLADEYO net revenue guidance.
    • VYNE Therapeutics Inc. (NASDAQ:VYNE) fell 9.3% to $0.2051 after jumping around 28% on Friday. VYNE Therapeutics, during November, posted a Q3 loss of $0.16 per share.
    • Neptune Wellness Solutions Inc. (NASDAQ:NEPT) fell 8.8% to $0.5901 after jumping around 35% on Friday. Neptune recently announced receipt of NASDAQ notification.
    • Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) shares fell 8% to $0.1334 after gaining over 10% on Friday.
    • Macy's, Inc. (NYSE:M) fell 7.7% to $20.42 after the company issued Q4 adjusted EPS and sales guidance.

    Also Check This Out Bitcoin Tops This Key Level; Gala, Solana Among Top Gainers

    Get the next $ALBO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALBO
    $AMYT
    $APGN
    $ARVN

    CompanyDatePrice TargetRatingAnalyst
    Macy's Inc
    $M
    3/19/2026$25.00 → $20.00Market Perform
    Telsey Advisory Group
    Tesla Inc.
    $TSLA
    3/4/2026$460.00Buy
    BofA Securities
    MARA Holdings Inc.
    $MARA
    2/27/2026Buy → Neutral
    H.C. Wainwright
    Snowflake Inc.
    $SNOW
    2/26/2026$275.00 → $282.00Buy
    Monness Crespi & Hardt
    Harmony Biosciences Holdings Inc.
    $HRMY
    2/23/2026Buy → Hold
    Deutsche Bank
    Harmony Biosciences Holdings Inc.
    $HRMY
    2/23/2026Buy → Hold
    Truist
    BioCryst Pharmaceuticals Inc.
    $BCRX
    2/18/2026$17.00Outperform
    Evercore ISI
    Tesla Inc.
    $TSLA
    2/12/2026$550.00Buy
    Tigress Financial
    More analyst ratings

    $ALBO
    $AMYT
    $APGN
    $ARVN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for DAXXIFY issued to REVANCE THERAPEUTICS, INC.

    Submission status for REVANCE THERAPEUTICS, INC.'s drug DAXXIFY (SUPPL-2) with active ingredient DAXIBOTULINUMTOXINA-LANM has changed to 'Approval' on 08/11/2023. Application Category: BLA, Application Number: 761127, Application Classification:

    8/14/23 4:38:56 AM ET
    $RVNC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DAXXIFY issued to REVANCE THERAPEUTICS, INC.

    Submission status for REVANCE THERAPEUTICS, INC.'s drug DAXXIFY (ORIG-1) with active ingredient daxibotulinumtoixnA-lanm has changed to 'Approval' on 09/07/2022. Application Category: BLA, Application Number: 761127, Application Classification:

    9/8/22 1:11:06 PM ET
    $RVNC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BYLVAY issued to ALBIREO PHARMA INC

    Submission status for ALBIREO PHARMA INC's drug BYLVAY (ORIG-1) with active ingredient ODEVIXIBAT has changed to 'Approval' on 07/20/2021. Application Category: NDA, Application Number: 215498, Application Classification: Type 1 - New Molecular Entity

    7/21/21 11:28:05 AM ET
    $ALBO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALBO
    $AMYT
    $APGN
    $ARVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tabacco Joseph J Jr bought $102,200 worth of shares (20,000 units at $5.11) (SEC Form 4)

    4 - BED BATH & BEYOND, INC. (0001130713) (Issuer)

    3/12/26 8:32:43 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Director Morrison Briggs bought $268,070 worth of shares (20,000 units at $13.40), increasing direct ownership by 26% to 96,021 units (SEC Form 4)

    4 - ARVINAS, INC. (0001655759) (Issuer)

    3/9/26 4:05:21 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Morrison Briggs bought $227,010 worth of shares (30,000 units at $7.57), increasing direct ownership by 65% to 76,021 units (SEC Form 4)

    4 - ARVINAS, INC. (0001655759) (Issuer)

    9/24/25 9:16:17 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALBO
    $AMYT
    $APGN
    $ARVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Telsey Advisory Group reiterated coverage on Macy's with a new price target

    Telsey Advisory Group reiterated coverage of Macy's with a rating of Market Perform and set a new price target of $20.00 from $25.00 previously

    3/19/26 7:55:45 AM ET
    $M
    Department/Specialty Retail Stores
    Consumer Discretionary

    BofA Securities resumed coverage on Tesla with a new price target

    BofA Securities resumed coverage of Tesla with a rating of Buy and set a new price target of $460.00

    3/4/26 8:40:18 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    MARA Holdings Inc. downgraded by H.C. Wainwright

    H.C. Wainwright downgraded MARA Holdings Inc. from Buy to Neutral

    2/27/26 11:05:23 AM ET
    $MARA
    EDP Services
    Technology

    $ALBO
    $AMYT
    $APGN
    $ARVN
    SEC Filings

    View All

    Grove Collaborative Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Grove Collaborative Holdings, Inc. (0001841761) (Filer)

    3/19/26 4:45:53 PM ET
    $GROV
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13D/A filed by Monte Rosa Therapeutics Inc.

    SCHEDULE 13D/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)

    3/19/26 4:05:18 PM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Snowflake Inc.

    144 - Snowflake Inc. (0001640147) (Subject)

    3/19/26 3:35:20 PM ET
    $SNOW
    Computer Software: Prepackaged Software
    Technology

    $ALBO
    $AMYT
    $APGN
    $ARVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Grove Collaborative and Oceanic Preservation Society Launch The Unplastic Shop to Help Consumers Reduce Plastic Exposure at Home

    Launched March 16, the new collection features ~500 vetted products and education to support practical, everyday swaps. Grove Collaborative Holdings, Inc. (NYSE:GROV) ("Grove" or "the Company"), the world's first plastic neutral retailer, leading sustainable consumer products company, Certified B Corporation, and Public Benefit Corporation, today announced a new partnership with Oceanic Preservation Society (OPS) to launch The Unplastic Shop—an education-led, curated shopping destination designed to help customers reduce plastic exposure where it matters most in everyday routines. For decades, plastic has been framed primarily as an environmental issue. Microplastics and certain chemica

    3/19/26 12:28:00 PM ET
    $GROV
    Catalog/Specialty Distribution
    Consumer Discretionary

    New apartment supply and rise of 'accidental landlords' help cool rent growth nationwide

    Rent growth slows to 1.9% amid persistent supply glut, giving renters more leverage after years of rapid rent increasesThe year-over-year increase in the typical U.S. asking rent eased to 1.9% in February, according to the Zillow Observed Rent Index.Nearly 40% of rental listings on Zillow offered concessions, such as free rent or waived fees, in February.While affordability is improving, a household needs to earn about $76,000 a year to afford the typical rent — nearly $20K more than before the pandemic.SEATTLE, March 19, 2026 /PRNewswire/ -- The rental market is recalibrating following years of rapid growth. In February, rents nationwide were up 1.9% from a year earlier, Zillow's latest Ren

    3/19/26 8:00:00 AM ET
    $Z
    $ZG
    Real Estate

    LexinFintech Holdings Ltd. Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results

    SHENZHEN, China, March 19, 2026 (GLOBE NEWSWIRE) -- LexinFintech Holdings Ltd. ("Lexin" or the "Company") (NASDAQ:LX), a leading technology-empowered personal financial service enabler in China, today announced its unaudited financial results for the quarter ended December 31, 2025. Mr. Jay Wenjie Xiao, Chairman and Chief Executive Officer of Lexin, commented, "The fourth quarter marked an important transition for us as we adapted to the new regulatory framework. Amid heightened industry risk volatility, our proactive compliance efforts and disciplined risk management enabled us to secure a stable transition, while balancing business scale and overall asset quality. Despite the complex m

    3/19/26 12:15:00 AM ET
    $LX
    Finance: Consumer Services
    Finance

    $ALBO
    $AMYT
    $APGN
    $ARVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Berkowitz Noah

    4 - ARVINAS, INC. (0001655759) (Issuer)

    3/19/26 8:01:54 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Thiel Frederick G

    4 - MARA Holdings, Inc. (0001507605) (Issuer)

    3/19/26 7:00:03 PM ET
    $MARA
    EDP Services
    Technology

    SEC Form 4 filed by Khan Salman Hassan

    4 - MARA Holdings, Inc. (0001507605) (Issuer)

    3/19/26 7:00:02 PM ET
    $MARA
    EDP Services
    Technology

    $ALBO
    $AMYT
    $APGN
    $ARVN
    Financials

    Live finance-specific insights

    View All

    LexinFintech Holdings Ltd. Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results

    SHENZHEN, China, March 19, 2026 (GLOBE NEWSWIRE) -- LexinFintech Holdings Ltd. ("Lexin" or the "Company") (NASDAQ:LX), a leading technology-empowered personal financial service enabler in China, today announced its unaudited financial results for the quarter ended December 31, 2025. Mr. Jay Wenjie Xiao, Chairman and Chief Executive Officer of Lexin, commented, "The fourth quarter marked an important transition for us as we adapted to the new regulatory framework. Amid heightened industry risk volatility, our proactive compliance efforts and disciplined risk management enabled us to secure a stable transition, while balancing business scale and overall asset quality. Despite the complex m

    3/19/26 12:15:00 AM ET
    $LX
    Finance: Consumer Services
    Finance

    Macy's, Inc. and Macy's Return to Annual Comparable Sales Growth; Fourth Quarter and Fiscal Year 2025 Results Exceed Guidance

    Bold New Chapter gained traction across all nameplates during fourth quarter, driven by go-forward stores and digital Bloomingdale's achieved its best holiday performance on record in the fourth quarter Macy's expands strategic initiatives to 75 additional stores, creating "Reimagine 200" for 2026 Macy's, Inc. (NYSE:M) today reported financial results for the fourth quarter and fiscal year 2025 and provided fiscal year 2026 guidance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318878750/en/ Fourth Quarter 2025 Highlights Macy's, Inc. net sales of $7.6 billion exceeded guidance. Macy's, Inc. comparable sales1 gr

    3/18/26 6:55:00 AM ET
    $M
    Department/Specialty Retail Stores
    Consumer Discretionary

    Barfresh to Announce Fourth Quarter and Fiscal 2025 Results on March 31, 2026

    LOS ANGELES, March 17, 2026 (GLOBE NEWSWIRE) -- Barfresh Food Group Inc. (the "Company" or "Barfresh") (NASDAQ:BRFH), a provider of frozen, ready-to-blend and ready-to-drink beverages, today announced that it will announce fourth quarter and fiscal 2025 results on Tuesday, March 31, 2026 at 1:30 pm Pacific Time (4:30 pm Eastern Time). Listeners can dial (877) 407-4018 in North America, and international listeners can dial (201) 689-8471. A telephonic playback will be available approximately two hours after the call concludes and will be available through Tuesday, April 14, 2026. Listeners in North America can dial (844) 512-2921, and international listeners can dial (412) 317-6671. Passco

    3/17/26 9:19:44 AM ET
    $BRFH
    Packaged Foods
    Consumer Staples

    $ALBO
    $AMYT
    $APGN
    $ARVN
    Leadership Updates

    Live Leadership Updates

    View All

    Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

    William "Obi" Greenman to become Executive Chairman Leadership changes to take effect July 1, 2026 Cerus Corporation (NASDAQ:CERS) today announced that Vivek Jayaraman, Cerus' chief operating officer, will be promoted to president and chief executive officer, effective July 1, 2026. William "Obi" Greenman will become executive chairman of the board of directors. At the time of his appointment, Mr. Jayaraman will join the Board of Directors. "Following a thorough succession planning process, this transition represents a natural step as we prepare for the next phase of growth at Cerus," said Frank Witney, lead independent director on the Cerus Board of Directors. "The Board and I are de

    3/16/26 4:05:00 PM ET
    $CERS
    EDP Services
    Technology

    RESAAS Appoints Michael Dziekan as Director of Data Strategy

    VANCOUVER, BC, March 12, 2026 /CNW/ - RESAAS Services Inc. ("RESAAS") (TSXV:RSS) (OTCQB:RSASF), a leading provider of technology solutions for the real estate industry, is pleased to announce the appointment of Michael Dziekan as Director of Data Strategy. Dziekan will lead RESAAS' data strategy initiatives, focused on expanding the Company's data partnerships, enhancing its global real estate data infrastructure, driving new opportunities for data-driven products and services across the RESAAS platform.Dziekan brings extensive global experience in real estate data, analytics, a

    3/12/26 8:30:00 AM ET
    $IBM
    $SNOW
    Computer Manufacturing
    Technology
    Computer Software: Prepackaged Software

    Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

    NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:  S&P MidCap 400 constituent Ciena Corp. (NYSE:CIEN) will replace Dayforce Inc. (NYSE:DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE:ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 9. Thoma Bravo L.P. acquired Dayforce in a deal that closed today.OneSpaWorld Holdings Ltd. (NASD: OSW) will replace Dynavax Technologies Corp. (NASD: DVAX) in the S&P SmallCap 600 effec

    2/4/26 6:15:00 PM ET
    $ADT
    $ARWR
    $CIEN
    Diversified Commercial Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALBO
    $AMYT
    $APGN
    $ARVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Xos Inc.

    SC 13D/A - Xos, Inc. (0001819493) (Subject)

    12/9/24 3:57:56 PM ET
    $XOS
    Auto Parts:O.E.M.
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Xos Inc.

    SC 13D/A - Xos, Inc. (0001819493) (Subject)

    12/9/24 3:45:37 PM ET
    $XOS
    Auto Parts:O.E.M.
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Lufax Holding Ltd

    SC 13D/A - Lufax Holding Ltd (0001816007) (Subject)

    12/9/24 6:12:27 AM ET
    $LU
    Finance: Consumer Services
    Finance